Why cost and treatment length are some of the biggest concerns for drug manufacturers.
What the future of specialty drugs holds for healthcare.
Each hospital and health system—and insurer—has unique circumstances, but there are several common approaches that are likely to help curb the growth in drug costs.
While the government shutdown doesn’t directly affect HHS, the shutdown is having profound and long-lasting effects on the U.S. healthcare system.
A look at what could be some of the biggest and most important drugs of the year.
Biosimilars hold great cost savings promises for payers and patients alike—but only if prescribers and patients are willing to make the switch.
Managed Healthcare Executive asked key opinion leaders their thoughts on the drug rebate controversy. Here’s what they said.
Are recent pharma price drops just a response to political pressure or will the momentum last? Managed Healthcare Executive asked industry experts, and here’s what they said.
To identify the top managed care pharmacy challenges and what your peers are doing about them, Managed Healthcare Executive conducted its annual pharmacy survey during the first quarter of 2018.
Healthcare experts weigh in on the president’s plan to lower drug prices. Here’s what they said.